Crinetics price target raised to $70 from $68 at Citi

Citi raised the firm’s price target on Crinetics to $70 from $68 and keeps a Buy rating on the shares post the Q1 pate. Following two positive paltusotine readouts in acromegaly and carcinoid syndrome in Q1, focus shifts to atumelnant, an ACTH antagonist in development for congenital adrenal hyperplasia and Cushing’s disease, the analyst tells investors in a research note.